Autologous– tag –
-
Northway Biotech Opens €61M Cell Therapy and Personalized Medicine CDMO in Vilnius, Marking Baltic Region’s First
PR Newswire Lithuania Overview Northway Biotech has launched a pioneering €61 million ($65M USD) cell therapy and personalized medicine CDMO facility in Vilnius, Lithuania, establishing the first such hub in the Baltics. This 3,500-squar... -
Technology Networks Delineates Commercialization Strategies for iPSC Therapies: Automated Manufacturing and Immune-Evasive Cell Line Development are Key
Technology Networks UK Overview Technology Networks provides an in-depth analysis of strategic challenges and solutions for the commercial viability of iPSC-based therapies, emphasizing the critical importance of scalable manufacturing, ... -
The Medicine Maker Forecasts Commercial-Scale iPSC Cell Therapy Hinges on Allogeneic Advances and Manufacturing Bottleneck Resolution
The Medicine Maker UK Overview The Medicine Maker reports that commercial-scale iPSC cell therapy hinges on the evolution of allogeneic cell therapies and the resolution of manufacturing bottlenecks. Stefan Braam, CTO of Cellistic, discu... -
Chemically Defined Media and Automation Key to Overcoming Raw Material Variability in Autologous Cell Therapies
BioProcess International International Overview Raw material variability poses a significant challenge to consistent manufacturing and quality in autologous adoptive cell therapies. Overcoming this requires chemically defined media, stan... -
Cell Grand Clinic in Japan Offers Non-Surgical Joint Pain Therapy: Culturing up to 200 Million Autologous Adipose-Derived Stem Cells over 7 Weeks for Direct Injection
Cell Grand Clinic Japan Overview Japan's Cell Grand Clinic announced its offering of a non-surgical joint pain therapy, involving the 7-week culture of autologous stem cells derived from a patient's fat, with up to 200 million cells inje... -
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA... -
Kyoto University iPSC Research Foundation Opens ‘Yanai my iPS Manufacturing Facility’ to Massively Enhance Clinical-Grade Autologous iPSC Production in Japan
BigGo Finance Japan Overview In 2025, with a substantial investment from Uniqlo founder Tadashi Yanai, the Kyoto University iPSC Research Foundation officially opened the 'Yanai my iPS Manufacturing Facility.' This marks Japan's first cl... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra...
